Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

13.45
+0.42003.22%
Post-market: 13.450.0200+0.15%16:32 EDT
Volume:990.80K
Turnover:13.20M
Market Cap:1.41B
PE:-9.29
High:13.58
Open:12.98
Low:12.61
Close:13.03
Loading ...

Edgewise Therapeutics Inc : JP Morgan Raises Target Price to $44 From $42

THOMSON REUTERS
·
19 Dec 2024

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Zacks
·
17 Dec 2024

Edgewise Therapeutics price target raised to $50 from $45 at Evercore ISI

TIPRANKS
·
17 Dec 2024

Buy Rating for Edgewise Therapeutics Driven by Promising CANYON Trial Results

TIPRANKS
·
17 Dec 2024

Edgewise Therapeutics Reports Promising Phase 2 Trial Results

TIPRANKS
·
17 Dec 2024

Promising Outlook for Edgewise Therapeutics: Buy Rating Reaffirmed with Increased Price Target

TIPRANKS
·
17 Dec 2024

Edgewise Therapeutics price target raised to $50 from $44 at Leerink

TIPRANKS
·
17 Dec 2024

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Benzinga
·
17 Dec 2024

Edgewise Therapeutics Inc : RBC Raises Target Price to $56 From $44

THOMSON REUTERS
·
17 Dec 2024

Edgewise Therapeutics Shares Higher on Positive Trial Results

Dow Jones
·
16 Dec 2024

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires Live
·
16 Dec 2024

Looming Fed Rate Decision, Key Data Drive Narrow Premarket Gains for US Equity Futures

MT Newswires Live
·
16 Dec 2024

Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell

MT Newswires Live
·
16 Dec 2024

Top Premarket Gainers

MT Newswires Live
·
16 Dec 2024

BUZZ-Edgewise Therapeutics gains as genetic disorder drug meets mid-stage study goal

Reuters
·
16 Dec 2024

Edgewise Therapeutics Shares ‍up 8.6% Premarket After Co's Genetic Disorder Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
16 Dec 2024

Edgewise reports CANYON Phase 2 trial of sevasemten meets primary endpoint

TIPRANKS
·
16 Dec 2024

Edgewise Therapeutics Inc - Key Secondary Endpoint Showed Trend Towards Improvement

THOMSON REUTERS
·
16 Dec 2024

Edgewise Therapeutics Inc - Sevasemten Was Well-Tolerated and No New Safety Concerns Were Observed

THOMSON REUTERS
·
16 Dec 2024

Edgewise Therapeutics Inc - Trial Met Primary Endpoint of Change in CK Levels

THOMSON REUTERS
·
16 Dec 2024